| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895057 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(4 years from now) | |
| US9011906 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(4 years from now) | |
| US9011905 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(4 years from now) | |
| US8895058 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(4 years from now) | |
| US8580298 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(5 years from now) | |
| US8580299 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(5 years from now) | |
Qsymia is owned by Vivus.
Qsymia contains Phentermine Hydrochloride; Topiramate.
Qsymia has a total of 6 drug patents out of which 0 drug patents have expired.
Qsymia was authorised for market use on 17 July, 2012.
Qsymia is available in capsule, extended release;oral dosage forms.
Qsymia can be used as use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight.
The generics of Qsymia are possible to be released after 14 June, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 24, 2025 |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Market Authorisation Date: 17 July, 2012
Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QSYMIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic